Targeting Iron Deficiency Anemia in Heart Failure

详细信息    查看全文

• 作者：Tajinderpal Saraon ; Stuart D. Katz ; ^{Stuart.Katz@nyumc.org" class="auth_mail" title="E-mail the corresponding author}
• 关键词：6MWT ; 6-minute walk test ; CV ; cardiovascular ; DMT-1 ; divalent metal transporter-1 ; FCM ; ferric carboxymaltose ; HF ; heart failure ; IRP ; iron regulatory proteins ; KCCQ ; Kansas City Cardiomyopathy Questionnaire ; LV ; left ventricular ; LVEF ; left ventricular ejection fraction ; MLWHF ; Minnesota Living With Heart Failure ; NT-pro BNP ; N-terminal-pro brain natriuretic peptide ; NYHA ; New York Heart Association ; QoL ; quality of life ; VO2 ; oxygen consumption or uptake ; WHO ; World Health Organization
• 刊名：Progress in Cardiovascular Diseases
• 出版年：2016
• 出版时间：January-February 2016
• 年：2016
• 卷：58
• 期：4
• 页码：407-415
• 全文大小：459 K

文摘

Iron deficiency is common in heart failure (HF) patients, and is associated with increased risk of adverse clinical outcomes. Clinical trials of intravenous iron supplementation in iron-deficient HF patients have demonstrated short-term improvement in functional capacity and quality of life. In some trials, the benefits of iron supplementation were independent of the hemoglobin levels. Additional investigations of iron supplementation are needed to characterize the mechanisms contributing to clinical benefit and long-term safety in HF.